ZORATRALCopy

• DRUGBANK - Alfuzosin
• indication:

  For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.

• pharmacology:

• mechanism:

  Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

• toxicity:

  Side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

• absorprion:

  Absorption is 50% lower under fasting conditions

• halflife:

  10 hours

• roouteelimination:

  Following oral administration of 14C-labeled alfuzosin solution, the recovery of radioactivity after 7 days (expressed as a percentage of the administered dose) was 69% in feces and 24% in urine.

• volumedistribution:

  * 3.2 L/kg [healthy male middle-aged volunteers]

• clearance: